Natera presents new Signatera colorectal cancer data at ESMO showing 10x benefit in overall survival Page 1

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will present new data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, at the European Society for Medical Oncology (ESMO) 2024 Congress, taking place September 13-16 in Barcelona, ​​Spain.

Natera and her collaborators will present a total of nine abstracts, including five poster presentations from the GALAXY observational arm of the CIRCULATE-Japan study, one of the largest and most comprehensive prospective studies of MRD testing in resectable colorectal cancer (CRC).